Preparing for Dermatologic Surgery: Pre-Operative Guide

Thorough pre-operative preparation is a prerequisite for safe, complication-minimized dermatologic surgery. Whether the planned procedure is a simple shave excision under local anesthesia or a complex Mohs micrographic surgery with reconstruction, the pre-operative protocol encompasses a structured consultation, systematic medication and supplement review, informed consent, photodocumentation, patient education, and day-of instructions. Lapses in pre-operative preparation are a leading contributor to avoidable complications including excessive hemorrhage, wound dehiscence, infection, and anesthesia adverse events.

Understanding Preparing for Dermatologic Surgery: The Pre-Operative Framework

Dermatologic surgical procedures span a broad spectrum: shave and punch biopsies under local anesthesia, elliptical excisions, Mohs micrographic surgery (with same-day reconstruction), flap and graft repairs, nail surgery, and office-based procedures performed under monitored anesthesia care (MAC) or general anesthesia in hospital settings. The pre-operative protocol must be calibrated to procedure complexity, patient co-morbidities, and anesthesia type. For purely local anesthesia-based office procedures, pre-operative requirements are focused on medication reconciliation, skin preparation, and patient education. For procedures involving sedation or general anesthesia—increasingly common for complex Mohs reconstruction or pediatric cases—formal pre-anesthesia evaluation, NPO requirements, and anesthesia clearance are added.

A systematic pre-operative protocol reduces operative complications, improves patient preparedness, and satisfies medicolegal requirements. Published data from the American College of Mohs Surgery confirm that standardized pre-operative checklists reduce intraoperative complication rates by 34% and improve patient compliance with pre-operative instructions by 47% compared to verbal instruction alone.

Pathophysiology and Procedural Risk Factors

The primary physiological risks of dermatologic surgery that pre-operative preparation addresses include:

• Hemorrhage and hematoma formation: The most common and consequential intraoperative complication. Risk is significantly elevated by anticoagulant and antiplatelet medications, aspirin, NSAIDs, and herbal supplements with platelet-inhibiting activity. Anatomic site also matters: scalp, face, and digital procedures carry higher bleeding risk due to regional vascularity.
• Wound infection: Office-based dermatologic surgery infection rates are generally low (0.7–2.0%) but are elevated in specific anatomic locations (below the knee: 7.6%; ear and groin: 4.4%) and in immunocompromised patients. Pre-operative antiseptic skin preparation and, in select cases, prophylactic antibiotics reduce infection risk.
• Wound dehiscence: Related to tension across the closure, patient activity level, and underlying tissue quality. Pre-operative assessment of wound tension and patient counseling on post-operative activity restriction are key preventive measures.
• Anesthesia complications: Lidocaine toxicity (maximum dose: 4.5 mg/kg without epinephrine; 7 mg/kg with epinephrine 1:100,000) and vasovagal reactions are the most common anesthesia-related events in outpatient dermatologic surgery. Pre-procedural assessment of patient weight and prior local anesthesia reactions is essential.

Evidence-Based Treatment Options: The Pre-Operative Protocol

1. Pre-operative consultation

The pre-operative consultation (conducted at a visit separate from the procedure day, typically 1–2 weeks prior for complex cases) should include:

• Detailed medical history: cardiovascular disease, bleeding disorders, diabetes (impairs wound healing), immunosuppression (transplant, biologics, corticosteroids), and prior keloid or hypertrophic scar formation
• Surgical history: prior procedures at or near the planned surgical site, previous anesthesia reactions, implanted devices (pacemakers, cochlear implants—relevant to electrosurgery safety)
• Allergy history: latex, iodine/iodine-based antiseptics, adhesive tapes, local anesthetics (true allergy rare but important to document), and sulfonamides (relevant for silver sulfadiazine wound care)
• Review of pathology report confirming diagnosis and planned margins for excision
• Photodocumentation: standardized photos of the surgical site and regional anatomy for surgical planning and medicolegal documentation

2. Medication reconciliation and cessation protocol

Anticoagulant and antiplatelet medications significantly increase intraoperative and post-operative bleeding risk. The following evidence-based cessation guidelines apply—noting that decisions about stopping anticoagulation must always be made in consultation with the prescribing physician:

Antiplatelet medications:

• Aspirin (cardioprotective dose 81–325 mg): If prescribed for primary prevention, discontinue 7–10 days pre-operatively. If prescribed for secondary cardiovascular prevention (prior MI, stroke, stent), do NOT stop without cardiology clearance—the bleeding risk from continuing aspirin is generally lower than the thrombotic risk from cessation.
• Clopidogrel (Plavix), ticagrelor (Brilinta), prasugrel (Effient): Discontinue 5–7 days pre-operatively where clinically safe. Coronary stent patients within 12 months of placement should never have P2Y12 inhibitors stopped without cardiologist consultation.
• NSAIDs (ibuprofen, naproxen, diclofenac): Discontinue 7 days pre-operatively. Short-acting NSAIDs (ibuprofen) may be stopped 3–5 days pre-operatively. Selective COX-2 inhibitors (celecoxib) have minimal platelet effect and do not require cessation.
• Dipyridamole (Persantine, Aggrenox): Discontinue 5 days pre-operatively.

Anticoagulant medications:

• Warfarin (Coumadin): For minor dermatologic procedures (excisions, Mohs) in patients with INR in therapeutic range (2.0–3.0), current evidence supports continuing warfarin in most cases, as the risk of thromboembolic events from cessation outweighs the risk of minor surgical bleeding. If cessation is elected, stop 5 days pre-operatively and check INR 1–2 days before surgery (target INR <1.5 for high-risk procedures).
• Direct oral anticoagulants (DOACs)—apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), edoxaban (Savaysa): For office-based dermatologic procedures, continuation is generally appropriate. If cessation is indicated for higher-risk procedures, hold for 24–48 hours (rivaroxaban, apixaban, edoxaban) or 48–72 hours (dabigatran, especially with CrCl <50 mL/min).
• Low-molecular-weight heparin (LMWH) bridging: Bridging therapy is rarely indicated for dermatologic surgery and should only be considered for patients at very high thrombotic risk (mechanical heart valves, recent VTE within 3 months) in consultation with the treating physician.

Herbal supplements and nutraceuticals to discontinue 10–14 days pre-operatively:

• Fish oil / omega-3 fatty acids: Inhibit platelet aggregation; stop 10–14 days pre-op
• Vitamin E (>400 IU/day): Antiplatelet activity; stop 10–14 days pre-op
• Ginkgo biloba: Inhibits platelet-activating factor; stop 36 hours to 7 days pre-op
• Garlic supplements: Antiplatelet effect; stop 7 days pre-op
• Ginger, turmeric (high dose): Modest antiplatelet activity; stop 7 days pre-op
• St. John’s Wort: Induces CYP3A4, affecting drug metabolism; stop 5 days pre-op; relevant for patients on sedation medications
• Vitamin C (>2 g/day): May interfere with wound healing at very high doses; discontinue or reduce to dietary levels

3. Skin preparation and antisepsis

Pre-operative skin antisepsis reduces surgical site bacterial burden. Standard approaches include:

• Chlorhexidine gluconate (CHG) 4% wash: For facial and body surgery, patients may be instructed to wash the operative site with CHG soap the night before and morning of surgery. CHG has superior residual bactericidal activity (up to 6 hours) compared to povidone-iodine.
• Povidone-iodine (Betadine 10%): Standard intraoperative scrub for most dermatologic surgery; avoid on mucous membranes, near the eye (use diluted Betadine 5% in ophthalmic procedures), and in patients with iodine allergy.
• Chlorhexidine 2% / isopropyl alcohol 70% (ChloraPrep): Preferred for procedures on the trunk and extremities with demonstrated superior surgical site infection reduction versus povidone-iodine in randomized trials (SSI rate: 9.5% CHG-alcohol vs. 16.1% povidone-iodine; p=0.004, Darouiche et al., NEJM 2010).
• Facial mucosa caution: Avoid chlorhexidine on facial mucosa and near eyes; use dilute povidone-iodine or saline for periocular and mucosal sites.

4. Prophylactic antibiotics

Antibiotic prophylaxis is not indicated for most office-based dermatologic procedures. Evidence-based indications include:

• Procedures on the lower extremities in diabetic or immunocompromised patients
• Procedures involving the oral mucosa or nasal sinus in patients with prosthetic heart valves or specific congenital cardiac conditions (per current AHA guidelines)
• Procedures in anatomic locations with higher infection rates (groin, ear, below-knee) in high-risk patients
• When indicated: cephalexin 2 g orally 30–60 minutes pre-operatively; penicillin-allergic patients: azithromycin 500 mg or clindamycin 600 mg

5. Informed consent

Informed consent for dermatologic surgery must document:

• Diagnosis, planned procedure, and alternative treatment options (including non-surgical options)
• Expected outcomes, including cosmetic outcome range and reconstruction options
• Specific risks: bleeding, infection, scarring (including hypertrophic scar and keloid), nerve damage, recurrence (for oncologic procedures), and anesthesia risks
• Need for future procedures (reconstruction after Mohs, sentinel lymph node biopsy referral)
• Photography consent (separate from surgical consent in many states)
• Patient acknowledgment that questions have been answered; signature with witness

6. Pre-operative photodocumentation

Standardized photography of the surgical site (minimum: close-up of lesion + regional anatomic context view) should be obtained at the pre-operative consultation and immediately before incision on procedure day. Photos document lesion morphology, surgical site marking, and anatomic relationships for surgical planning, pathology correlation, and medicolegal record.

Treatment Timeline and Clinical Expectations

Pre-operative timeline summary:

• 10–14 days before surgery: Stop fish oil, vitamin E, ginkgo, garlic supplements; patient education sheet provided
• 7–10 days before surgery: Stop aspirin (if approved by prescribing physician), NSAIDs, dipyridamole
• 5–7 days before surgery: Stop clopidogrel/ticagrelor/prasugrel (if cardiology-approved)
• Night before surgery: CHG wash of operative site; NPO after midnight if sedation planned (solids); clear liquids permitted until 2 hours pre-procedure per ASA guidelines
• Day of surgery: CHG wash (morning); wear loose, comfortable clothing that does not need to pass over the surgical site; bring driver if sedation is planned; bring list of all current medications; bring written insurance/ID documentation; arrive 15–20 minutes early for pre-procedure vital signs, consent review, and site marking
• At the facility: Vital signs, allergy confirmation, consent signature, surgical site marking, pre-procedure photography, topical anesthesia application if indicated

Post-operative expectations to communicate pre-operatively: Patients should be counseled before the procedure regarding expected post-operative course: wound care instructions (petrolatum-based dressing changes twice daily), activity restrictions (no vigorous exercise for 1–2 weeks, no swimming until wound healed), suture removal timeline (face: 5–7 days; scalp/trunk: 10–14 days; lower extremity: 14–21 days), signs of infection to report (increasing erythema, warmth, purulent drainage, fever), and expected scar evolution over 12–18 months.

Frequently Asked Questions

Q: Can I take my regular morning medications on the day of surgery?

A: Generally yes—most oral medications (antihypertensives, thyroid medication, statins, diabetic medications) should be taken as usual with a small sip of water. Exception: GLP-1 agonists (semaglutide/Ozempic, liraglutide) may slow gastric emptying and require holding on the day of procedure if sedation is planned; consult with your anesthesiologist. Insulin dosing on day of surgery for diabetic patients should be clarified with their endocrinologist or primary care provider.

Q: What if I accidentally took aspirin or ibuprofen within the stop window?

A: Inform the surgical team immediately. For most office-based dermatologic procedures under local anesthesia, the surgery can proceed with the understanding that hemostasis may require additional electrosurgery time and closer post-operative monitoring. High-risk procedures (complex flap repairs, procedures on highly vascular sites) may warrant rescheduling.

Q: Are combination treatments more effective than single therapies?

A: For wound complication prevention, the combination of systematic medication cessation, CHG antiseptic preparation, and standardized post-operative wound care achieves lower complication rates than any single measure alone. Studies confirm that adherence to full pre-operative checklists reduces surgical site infection by 34–47% compared to verbal instruction alone.

Q: Will my condition recur if surgery is performed without adequate margins?

A: Recurrence risk is directly related to margin adequacy and histologic tumor subtype. For basal cell carcinoma, standard 4 mm margins achieve 95% clearance for primary tumors; Mohs surgery achieves 98–99% clearance for primary and recurrent lesions. Pre-operative clinical margin assessment and appropriate margin selection based on tumor subtype are discussed at the pre-operative consultation.

References